Bevacizumab

Generic Name
Bevacizumab
Brand Names
Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi
Drug Type
Biotech
Chemical Formula
-
CAS Number
216974-75-3
Unique Ingredient Identifier
2S9ZZM9Q9V
Background

There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...

Indication

As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...

Associated Conditions
Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Associated Therapies
First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment
Clinical Trials
Related News

Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors

First Posted Date
2024-06-06
Last Posted Date
2024-12-19
Lead Sponsor
Revolution Medicines, Inc.
Target Recruit Count
406
Registration Number
NCT06445062
Locations
🇺🇸

HonorHealth Research Institute, Scottsdale, Arizona, United States

🇺🇸

UCLA Hematology/Oncology- Santa Monica, Los Angeles, California, United States

🇺🇸

University of Colorado Hospital-Anschutz Cancer Pavilion, Aurora, Colorado, United States

and more 14 locations

Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

First Posted Date
2024-06-03
Last Posted Date
2024-12-19
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
25
Registration Number
NCT06439485
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites

First Posted Date
2024-05-30
Last Posted Date
2024-05-30
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
60
Registration Number
NCT06433869
Locations
🇨🇳

Cancer center of SunYat-sen University, Guangzhou, Guangdong, China

🇨🇳

Zhang Dongsheng, Guangzhou, China

Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer

Phase 1
Not yet recruiting
Conditions
Colorectal Cancer
Interventions
Drug: Liposomal irinotecan
Drug: Bevacizumab
First Posted Date
2024-05-30
Last Posted Date
2024-05-30
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
74
Registration Number
NCT06434090
Locations
🇨🇳

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Combination Therapy for BRAF-V600E Metastatic CRCm

First Posted Date
2024-05-13
Last Posted Date
2024-11-08
Lead Sponsor
Vall d'Hebron Institute of Oncology
Target Recruit Count
94
Registration Number
NCT06411600
Locations
🇪🇸

Vall d'Hebron Hospital, Barcelona, Spain

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

First Posted Date
2024-05-01
Last Posted Date
2024-12-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
127
Registration Number
NCT06393751

Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial)

Phase 2
Recruiting
Conditions
Ovarian Cancer
Interventions
Drug: Bevacizumab
Drug: Olaparib
First Posted Date
2024-04-22
Last Posted Date
2024-05-09
Lead Sponsor
Vall d'Hebron Institute of Oncology
Target Recruit Count
100
Registration Number
NCT06377267
Locations
🇪🇸

Vall d'Hebron Institute of Oncology, Barcelona, Spain

SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases

Phase 2
Not yet recruiting
Conditions
Breasr Cancer
Interventions
Drug: SHR-A1811
Drug: Bevacizumab
First Posted Date
2024-04-12
Last Posted Date
2024-04-12
Lead Sponsor
Huihua Xiong
Target Recruit Count
30
Registration Number
NCT06361979

Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer

First Posted Date
2024-04-02
Last Posted Date
2024-08-12
Lead Sponsor
West China Hospital
Target Recruit Count
86
Registration Number
NCT06341296
Locations
🇨🇳

West China Hospital，Sichuan University, Sichuan, Sichuan, Chengdu, China

Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer

Phase 1
Not yet recruiting
Conditions
Metastatic Colorectal Cancer
Interventions
Drug: Irinotecan Liposome
Drug: Bevacizumab
First Posted Date
2024-04-02
Last Posted Date
2024-08-09
Lead Sponsor
West China Hospital
Target Recruit Count
20
Registration Number
NCT06341309
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy